- Home
- IMPP vs LUCD Comparison
IMPP vs LUCD Comparison
Compare IMPP & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | LUCD |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMPP | LUCD |
|---|---|---|
| Price | $4.12 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $5.50 | $3.94 |
| AVG Volume (30 Days) | ★ 1.2M | 720.5K |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $136,071,654.00 | $4,399,000.00 |
| Revenue This Year | $9.69 | $12.31 |
| Revenue Next Year | $51.33 | $152.14 |
| P/E Ratio | $4.10 | ★ N/A |
| Revenue Growth | N/A | ★ 5.01 |
| 52 Week Low | $2.12 | $0.75 |
| 52 Week High | $6.57 | $1.80 |
Technical Indicators
Market Signals| Indicator | IMPP | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 52.35 |
| Support Level | $4.04 | $1.02 |
| Resistance Level | $4.49 | $1.16 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 4.05 | 66.24 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.